Outsourcing motivations are important considerations to identifying the best outsourcing approach and should influence the type of relationships your organization develops with CMOs. Data comes from ISR’s CMO Quality Benchmarking suite of market research reports and ISR’s Development and Commercial Outsourcing Models market research report.
ISR has observed use of Preferred Provider agreements and the proportion of outsourcing allocated to Preferred Providers increase over the past three years. Is it because PPAs are the best model for outsourced manufacturing?
Industry Standard Research explains how Life Science Leader’s CMO Leadership Awards and the corresponding market research data, can be used by biopharma companies to make more informed CMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.
In the past 50 years, since the onset of the digital age, the world has been transformed by technology. In the last decade, we’ve seen technology further disrupt the way we shop, communicate, and get from point A to point B.
A look at which departments at sponsor organizations are involved in the decision-making process and how much decision-making responsibility each department has for outsourcing various late-phase study activities.
To improve our understanding of the supplier traits on which buyers of outsourced services focus, ISR asked (in our Bioprocessing Market Dynamics survey) a hypothetical question.
An unexpected finding from ISR’s research with regards to contract manufacturing from the perspective of a market researcher. The data come from Industry Standard Research’s CDMO Outsourcing Models survey.
Results of a survey asking interviewees about their preferred category of CMO for a certain type of outsourced manufacturing work — full-service CDMOs with end-to-end capabilities or specialty contract manufacturers with expertise in particular areas of need.
This year’s CMO Leadership Awards result from feedback obtained through four different contract manufacturing surveys — biologic API, biologic drug product, small molecule API, and small molecule drug product — conducted by Industry Standard Research.
Over the past several decades, the practice of outsourcing has evolved from transactional, client-vendor relationships where cost savings were the primary focus, to preferred provider relationships with pre-vetted companies to start up projects quickly and then to relationships more strategic in nature to gain access to technologies, skills, or expertise not possessed in-house.
There has been an important evolution in the CMO awards this year, which better aligns with some of the Nice Insight research findings that regularly make their way into this column. When it comes to finding the “right” CMO, the qualities that comprise what makes the CMO the “right” one are different among the various buyers of outsourced services.
In 2014, the biopharmaceutical industry witnessed more and more contract suppliers take on the CDMO (contract development and manufacturing organization) acronym to identify their ability to assist at the development stage of drug manufacturing. These businesses can provide comprehensive services, from drug development through to manufacturing commercial supply, and are interested in differentiating their abilities from CMOs focused solely on large-scale manufacturing projects.
Now into the fifth year of examining outsourcing behaviors and ways contract suppliers can improve the drug development process, the results from the 2015 Nice Insight Biopharmaceutical Outsourcing Survey show that the biopharmaceutical industry is making some subtle changes in how it prioritizes companies when it comes to selecting a CRO or CMO.
2014 was an exciting year in outsourcing. Several high profile mergers and acquisitions in both the CRO and CMO world will mean some familiar names will go through big changes — Huntingdon acquired Harlan, and PRA acquired RPS in the CRO world; Patheon acquired both DSM and Gallus Biopharma, and AMRI acquired Cedarburg and OsoBio in the CMO world.
According to clinicaltrials.gov, there are over 92,000 drug or biologic registered studies under way right now. Nearly one-fifth (17 percent) of the drugs currently in development are biologic-based therapeutics.